PHAR · Pharming Group N.V. ADS each representing 10
Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow PHAR by emailGet an email when PHAR pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PHAR, unsubscribe in one click. Privacy
📣 What PHAR Says Is Next
fourth quarter of 2026 · “Pharming expects to report Phase II results for leniolisib in CVID patients with immune dysregulation, with or without an identified genetic cause, in the fourth quarter of 2026.”
Company press release, Sep 22, 2026 · SEC filing
fourth quarter of 2026 · “Patient enrollment in both clinical trials is complete and we anticipate trial read-outs in the fourth quarter of 2026, consistent with prior guidance.”
Company press release, Jul 30, 2026 · SEC filing
fourth quarter 2026 · “Plans to report clinical data with leniolisib in significantly larger CVID patient populations in the fourth quarter 2026”
Company press release, Jul 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full PHAR picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PHAR and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.